Information presented is for educational and reference purposes and does not constitute medical, scientific or professional advice
Inflammatory Bowel Disease (IBD) Models: The cytoprotective properties observed in the stomach were subsequently investigated in models of IBD, such as colitis induced by TNBS or DSS in rats
Stop and Seek Help If Severe allergic reaction (rash, swelling, difficulty breathing) Persistent severe nausea or vomiting not improving with dose reduction Signs of pancreatitis (severe abdominal pain radiating to back) Planned pregnancy or positive pregnancy test Inability to maintain adequate nutrition despite dose adjustments Any concerning symptoms your healthcare provider advises stopping for Always consult your healthcare provider before stopping or modifying your dose
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
A lack of vitamin B12 leads to anaemia and sometimes to other problems
